Status:
RECRUITING
Recommendations for the Treatment of Children With Burkitt's Lymphoma
Lead Sponsor:
French Africa Pediatric Oncology Group
Conditions:
Burkitt Lymphoma
Eligibility:
All Genders
Up to 18 years
Brief Summary
This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response...
Detailed Description
This is the 4th Burkitt's Lymphoma (LMB) study by the GFAOP group. This study hopes to include at least 14 Sub Saharian countries some of whom have never participated in a LMB study. The evaluation of...
Eligibility Criteria
Inclusion
- Clinical diagnosis of Burkitt's Lymphoma: all location. Diagnosis by cytology or histology. Not possible to follow all the treatment.
- \-
Exclusion
- Not a B Cell tumor. Child has been previously treated. Child has also another illness which would render the treatment incompatible. Parents refusal.
Key Trial Info
Start Date :
November 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04425421
Start Date
November 1 2020
End Date
December 31 2028
Last Update
October 3 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Yalgado Ouedraogo
Ouagadougou, Burkina Faso, 03 BP 7022
2
CHU de Treichville à ABIDJAN
Abidjan, Côte d’Ivoire
3
Cliniques Universitaires de Kinshasa
Kinshasa, Kinshasa City, Democratic Republic of the Congo, BP 12 KIN XI
4
Cliniques Universitaires de Lubumbashi (CUL)
Lubumbashi, Democratic Republic of the Congo, BP 1825